quantisnow
FeedTopReportsPricing
⌘K
Live feed
17:11:14·225d
SECFiling
Actuate Therapeutics Inc. logo

Actuate Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

ACTU· Actuate Therapeutics Inc.
Health Care
Original source

Companies

  • ACTU
    Actuate Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Aug 26UpdateB. Riley Securities$20.00
  • Apr 22UpdateCraig Hallum$21.00
  • Mar 17UpdateH.C. Wainwright$20.00

Related

  • PR9d
    Actuate Therapeutics Announces Nature Medicine Publication of Clinical Trial Results Showing Doubling of the Rate of Survival with Elraglusib Plus Chemotherapy in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
  • SEC17d
    SEC Form DEFA14A filed by Actuate Therapeutics Inc.
  • SEC17d
    SEC Form DEF 14A filed by Actuate Therapeutics Inc.
  • INSIDER22d
    SEC Form 4 filed by Schmitt Daniel M
  • INSIDER22d
    SEC Form 4 filed by Mazar Andrew Paul
  • INSIDER22d
    SEC Form 4 filed by Lytle Paul J
  • SEC28d
    SEC Form 10-K filed by Actuate Therapeutics Inc.
  • NEWS31d
    Actuate Therapeutics: Poised for Potential $200M+ Pediatric Priority Review Vouchers and Transformative Combinations in RAS-Driven Cancers
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022